Attention Pharmacists and Pharmacy Techs: NEW CE POLICY EFFECTIVE MAY 1, 2014 More Information
This home-study activity describes the impact of hyperglycemia in the critical care setting, as well as research on the development of clinical targets for optimal glycemic control.
Choose from the criteria below to find an activity that fits you best.
In today’s healthcare environment, medical devices are no longer viewed as isolated entities. The value of a device increases dramatically when it is a component of an aggregate process. In the case of infusion management, the connection between smart pumps and the electronic health record creates a closed-loop process that minimizes clinician error and immediately documents infusion data. This CE activity describes the value of a closed-loop infusion management process, emphasizing medication safety and work flow benefits to the multidisciplinary team.
The target audience for this CE activity is pharmacists. After completing this activity, the participant will be able to:
Summarize the most common types of medication errors in hospital settings
Describe the components of a closed-loop process for administration of drug infusions
Describe the pharmacist’s role in integrated infusion management
Outline the benefits of integrated infusion management in terms of patient safety, work flow efficiency, and institutional cost savings
Donald “Chip” Gerhart, Jr., RPh
Quality Assessment Manager
Department of Pharmacy
Kristen L. O’Shea, MS, RN, NEA-BC
Clinical Transformation Officer
Rebecca R. Prevost, PharmD
Medication Safety Officer
This CE activity is co-sponsored by ProCE, Inc. and Hospital Pharmacy. ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-13-020-H05-P has been assigned to this knowledge-based, home-study activity (initial release date 04-05-13). This activity is approved for 1.5 contact hours (0.15 CEU) in states that recognize ACPE providers. This CE activity is provided at no cost to participants. Statements of credit will be issued online upon completion of the evaluation and the post-test with a score of 70% or higher. No partial credit will be given.
Release Date: 04-05-2013
Expiration Date: 04-05-2016
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and
scientific rigor in all of its continuing education activities. Faculty must disclose
to participants the existence of any significant financial interest or any other relationship
with the manufacturer of any commercial product(s) discussed in an educational presentation.
Mr. Gerhart has served as a consultant and/or speaker for Hospira. Ms. O'Shea
has served as a consultant and/or speaker for Cerner and Hospira. Dr. Prevost has
no relevant commercial or financial relationships to disclose.
Please note: The opinions expressed in this activity should not be construed as those of the CME/CE provider. The information and views are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include the use of drugs for unlabeled indications. Use of drugs outside of labeling should be considered experimental and participants are advised to consult prescribing information and professional literature.
This activity is supported by an educational grant from Hospira, Inc.
The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.